As an investment advisor, you should know that the long term view is definitely the preferred why to look at stocks (at least for me!). Some people have better "gut" feelings or luck and can profit from short term price movements. I for one, buy and hold.
BCHE was supposed to start raking in the $ from the new drug the last Qtr. Instead, only $800K or so was generated. Some analysts had the numbers as high as $10M. Well, to save face they slammed the stock and its been floating around since than.
This Q, the numbers came in at >$10M. Great! Mnge stated after last Q that they would have revenue of $70M this year from the Hep-B drug. Looks like the numbers are picking up.
Here are some cut/paste items from one of your posts.
Message 1063009
Friday, July 23, 1999
"Investors are realizing that, while they really haven't been paying
attention, there has been a lot of value(in biotech's) that has been built up and often is still unrecognized in many of these companies," said Ezra Lwowski, an analyst at Yorkton Securities Inc. in Toronto.....
After the gains of the past seven weeks, there is still value in the
market, said Ann Dulhanty, an analyst at Dundee Securities Corp.
Ms. Dulhanty's current favourites are Biochem Pharma Inc. (BCH/TSE) and Synsorb Biotech Inc. (SYB/TSE) as well as StressGen Biotechnologies Corp. (SSB/TSE).
"They come into my category of fundamentally strong companies, and
they haven't appreciated as much as some in this current rally," she says....
Patiently waiting.
Jim |
